TEM · Updated
Tempus AI
Tempus AI is a US precision-medicine company that combines genomic and other diagnostic testing with AI tools and a large library of clinical and molecular data. In its latest fiscal year (ended 31 December 2025) it reported revenue of $1.27 billion and a net loss of $245.0 million, according to its 10-K filed on 24 February 2026. Bet The Decade has covered Tempus AI in 1 episode, most recently “This Cancer Lab Is Becoming an AI Giant” (27 October 2026).
Business description summarized from 10-K (Item 1, Business), filed 2026-02-24. Figures: SEC EDGAR, retrieved 5 November 2026.
Not investment advice. Educational content and opinion only. The author may hold shares in companies discussed. Disclosure
Not medical advice. Talk to a licensed clinician about any treatment.
Key data
| Field | Value | Source |
|---|---|---|
| Legal name (SEC) | Tempus AI, Inc. | SEC EDGAR, CIK 0001717115 |
| Ticker · exchange | TEM · Nasdaq | SEC submissions data |
| Industry (SEC SIC) | Services-Computer Programming, Data Processing, Etc. | SEC EDGAR company profile |
| Incorporated in | NV | SEC EDGAR company profile |
| Revenue, latest fiscal year | $1.27 billion · 1 January 2025 to 31 December 2025 | 10-K filed 2026-02-24 · XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax = 1,271,789,000 USD |
| Net income (loss), latest fiscal year | -$245.0 million · 1 January 2025 to 31 December 2025 | 10-K filed 2026-02-24 · XBRL us-gaap:NetIncomeLoss = -245,028,000 USD |
| Revenue, latest reported quarter | $411.5 million · 1 July 2026 to 30 September 2026 | 10-Q filed 2026-11-02 · XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax = 411,537,000 USD |
| Cash and cash equivalents | $590.5 million · as of 30 September 2026 | 10-Q filed 2026-11-02 · XBRL us-gaap:CashAndCashEquivalentsAtCarryingValue = 590,479,000 USD |
| Latest annual report | 10-K for period ending 31 December 2025 | Filed 2026-02-24 |
| Latest quarterly report (10-Q) | 10-Q for period ending 30 September 2026 | Filed 2026-11-02 |
SEC EDGAR
- All filingsSEC EDGAR · CIK 0001717115sec.gov
- Annual reports10-K filingssec.gov
- Quarterly / current10-Q filingssec.gov
- XBRL dataCompany facts (JSON)data.sec.gov
FAQ
Where can I read Tempus AI's official filings?
Tempus AI files with the US Securities and Exchange Commission under CIK 0001717115. Its annual and quarterly reports are on SEC EDGAR.
Sources: sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001717115
What does Tempus AI do?
Tempus provides genomic sequencing, clinical data platforms and AI applications for oncology and other care settings.
Sources: tempus.com/ · investors.tempus.com/
Main risks?
Reimbursement, competition in diagnostics, and data/privacy regulation.
Sources: investors.tempus.com/
Episodes
Themes: Biotech
Page status: Complete. Last updated 5 November 2026.